Our Scientific Advisory Board is an external body of experts in the computational science domain. These experts represent the global scientific user community, with a special focus on representation from outside Europe. Their role is to advise on development and dissemination of the Open PHACTS Discovery Platform with respect to scientific disciplines.
My early research focused on NMR spectroscopy of organometallic systems, using heteronuclear NMR to study molecular structure and dynamics in solution. This led to applications to macromolecular systems with publications on proteins, DNA and carbohydrate systems. In particular the 1993 publication of the 3D NMR structure of heparin (with Barbara Mulloy), has subsequently been validated many times by X-ray and other methods. This structure determination required careful and novel analysis of NMR nOe data using methods developed by me. This interest in scientific software development led me to spend 5 years in the commercial software domain working for Biosym in the gentle and pleasant climate of San Diego.
Since 2001 I have worked for Syngenta R&D Information Systems, firstly in the domain of developing and supporting systems for plant biotechnology. I also manged the team supporting company efforts in chemical informatics and bioinformatics for chemical discovery. My current role is focussed on data and information standards, software tools and collaborations in support of R&D goals.
I maintain a keen interest in technical and research computing and in the scientific literature in the fields of quantum chemistry, molecular simulation and databases, small molecule and protein structure, informatics and many kinds of data analysis and visualisation techniques.
One recent highlight was the Syngenta and Wellcome Trust funded meeting on ‘Molecular Informatics Open Source Software’ or MIOSS 2011, that I conceived, organised and chaired. Considered by several participants as a ground breaking forum for industry and the open source community to collaborate and innovate, it is a concept and event in which I take great pride.
Education: Ph.D Chemistry, London University
- Researcher, University of Lausanne, Institut de Chemie Minerale et Analytique, Switzerland.
- Senior research officer, National Institute for Medical Research (NIMR), Mill Hill, London, UK
- Scientist/Principal scientist. National Institut for Biological Standards and Control (NIBSC), South Mimms, Hertfordshire, UK.
- Developer / Manager for protein application product development. Biosym (Now Accelrys), San Diego, California, USA.
- Senior information domain specialist. Syngenta R&D Information Systems (RDIS) International Research Centre, Jealott’s Hill, Berkshire, UK.
Dean Allemang specializes in innovative applications of knowledge technology, is Founder and Principal Consultant at Working Ontologist LLC., a consultancy specializing in semantic web applications, currently with an industry focus in Finance and Pharmaceuticals. Formerly Chief Scientist at TopQuadrant, Inc., he has over 15 years experience in research, deployment and development of Semantic Technology systems.
Dean has worked and studied extensively abroad as a Marshall Scholar at Trinity College, Cambridge. No stranger to innovation, he was twice winner of the Swiss Technology Prize. He has been keynote speaker for a number of Semantic Web conferences, including the Semantic Technologies conference, the OWLED workshop, RuleML and at the 3rd Joint International Semantic Web Conference.
As an internationally recognized expert in the Semantic web, he participated in the review board for the Digital Enterprise Research Institute-the world’s largest Semantic Web research institute. He lead TopQuadrant’s successful TopMIND training series, from which he drew much of the inspiration for his bestselling book (co-authored with Prof. Jim Hendler), Semantic Web for the Working Ontologist, now in second edition. Other book contributions include Abductive Inference (Josephson and Josephson, eds.) and Linking Enterprise Data (Wood, ed.). Dr. Allemang combines a strong formal background (MSc in Mathematics, University of Cambridge, PhD in Computer Science, Ohio State University) with years of experience applying knowledge-based technologies to real business problems.
Dr Michael Barnes has over 14 years of Pharma R&D experience and was recently appointed Director of Bioinformatics at the William Harvey Research Institute, Queen Mary University of London. He previously led a computational biology team at GlaxoSmithKline focused on translational research for neuroscience drug discovery. After leaving GSK, he co-founded OI Pharma Partners, with Dr Jackie Hunter (www.oipharma.com). The company advocates the use of open innovation as a tool to stimulate R&D in the pharma and healthcare sectors. This work continues alongside his main focus of research on the use of genomic data to for drug discovery and better patient stratification. Michael has consistently championed pre-competitive collaboration and partnership between industry and academia. He co-led the original EFPIA team to propose the Open PHACTS project and continues to take a close interest in the project now from an academic perspective. Now working both in academia and biotech he is working hard to better understand and enhance the collaborative interface between the two sectors, towards the ultimate goal of clinical translation.
At the Massachusetts General Hospital, Tim’s group has led and collaborated in development of several important biomedical ontologies, notably the SWAN scientific discourse ontology, and AO, the Annotation Ontology. His laboratory developed the Domeo Web Annotation Toolkit (www.annotationframework.org) for storing, visualizing, curating and combining the results of biomedical textmining on web documents, and several important biomedical web communities.
Tim serves on the Executive Committee for the Massachusetts Alzheimer Disease Research Center (www.madrc.mgh.harvard.edu) and co-leads its Data and Statistics Core. He also serves on the Editorial Board of the journal Briefings in Bioinformatics, and the Advisory Board of the NIH Neuroscience Information Framework.